Digital pathology AI: which tools have real deployment data
Digital pathology AI is the loudest pitch deck space in medicine. Here’s the directory of tools that have validation data and active deployments.
But before we dive into the vendors, let’s be clear about what “deployment” actually means. It’s not just about licensing software. It’s a massive capital investment in whole-slide imaging (WSI) scanners, high-performance computing, and petabytes of storage. For a pathology group, this is a strategic and financial decision on par with a radiology group buying a new 3T MRI. Getting the financial structure right from day one is the difference between a successful, profitable transition and a capital-intensive nightmare.
This article provides the financial playbook for that investment. We’ll start with a brief overview of the major AI players and then pivot to the critical tax and ownership strategies that make these deals pencil out for physician-owners. For a continuously updated list of vendors and clinical applications, see our complete guide to pathology AI tools and resources.
The Shortlist: AI Tools with Real-World Traction
The AI pathology market is crowded, but a few platforms have moved beyond research and into active clinical use, backed by regulatory clearance and published validation studies. These are the names that repeatedly appear in deployment discussions at major academic centers and large private practice groups.
- Paige: One of the first to gain FDA approval, Paige started with a focus on prostate cancer detection in biopsies (Paige Prostate) and has since expanded to breast cancer and a broader full-slide image viewer. Their key differentiator was early integration with large health systems, generating substantial real-world data.
- PathAI: PathAI has a strong presence in both clinical diagnostics and biopharma research. Their work with drug development partners gives them access to vast datasets, which they leverage to build algorithms for applications like PD-L1 scoring and tumor microenvironment analysis.
- Ibex Medical Analytics: The Galen™ platform from Ibex has gained significant traction, particularly in Europe with CE-IVD marking, and has FDA clearance for specific applications. It’s designed as an “AI-powered safety net,” helping pathologists identify missed cancers and improve diagnostic consistency in areas like breast and prostate pathology.
- Aiforia: Aiforia provides a cloud-based platform with a suite of tools for various tissue types, including lung, breast, and prostate cancer. They emphasize user-friendliness, allowing pathologists to create their own AI models for specific research or clinical needs, in addition to using pre-built algorithms.
This is just a snapshot. The landscape is dynamic, with new clearances and partnerships announced regularly. You can explore a more comprehensive and filterable list in the physician AI tools directory. However, selecting the right algorithm is only step one. Step two is financing the multi-million dollar infrastructure it runs on.
Section 179 & Bonus Depreciation: Your First-Year CapEx Shield
Let’s say your group decides to invest $1.5 million in two high-throughput WSI scanners and the requisite server/storage infrastructure. This is where the tax code becomes your most important partner. Under Section 179 of the IRS code, you can immediately expense a significant portion of this cost in the year of purchase, rather than depreciating it slowly over 5-7 years.
For 2026, the Section 179 deduction limit is $1.16 million. This means you can deduct that amount directly from your practice’s income. But what about the remaining $340,000? That’s covered by 100% bonus depreciation. Bonus depreciation allows you to deduct the full cost of qualifying new and used equipment in the first year, and it applies after the Section 179 limit is reached.
The result: Your group’s $1.5 million investment generates a $1.5 million tax deduction in year one. For a practice with, say, $4 million in taxable income, this instantly reduces it to $2.5 million. For the partners, that translates to a massive reduction in their personal tax liability for the year, effectively providing a significant government-funded “rebate” on your capital expenditure.
The Trap: The equipment must be “placed in service” by December 31st of the tax year. We’ve seen groups sign a purchase order in December, but the scanner doesn’t arrive and get installed until February. That pushes the entire deduction into the next tax year, creating a major, unexpected tax bill. Your purchase timeline must be managed with your accountant and vendor to ensure it’s operational before year-end.
The Equipment Leasing Entity: A QBI Strategy for High-Income Pathologists
Most practicing pathologists are well above the income thresholds for the Qualified Business Income (QBI) deduction under Section 199A. Because medicine is classified as a “Specified Service Trade or Business” (SSTB), the 20% pass-through deduction phases out completely for physicians with taxable income over approximately $394,000 (single) or $787,000 (joint) in 2026.
Here’s a potential workaround used by many equipment-heavy specialties. The physician partners form a separate legal entity, typically an LLC, that is not an SSTB. This “equipment entity” (EquipCo) buys the scanners and servers. EquipCo then leases the equipment to the pathology practice (PathGroup) at a fair market rate.
Here’s the flow:
- EquipCo buys the $1.5M in scanners and takes the full Section 179/bonus depreciation, creating a large paper loss in year one. This loss passes through to the partners, sheltering other income.
- PathGroup pays EquipCo a monthly lease fee. This is a deductible business expense for the practice.
- EquipCo receives this lease payment as rental income. Because equipment leasing is generally *not* an SSTB, this income may be eligible for the 20% QBI deduction, even though the partners’ clinical income is not.
The Trap: This is not a DIY strategy. The IRS has strict aggregation rules (§1.199A-4) that govern how related entities are treated. The lease must be at a commercially reasonable, arm’s-length rate. The entities must have proper legal separation and accounting. This requires a CPA who is an expert in structuring these arrangements for medical practices to ensure it withstands scrutiny.
Outpatient Lab Ownership: Structuring Your Digital Pathology Venture
Going digital may coincide with establishing a new outpatient lab or a joint venture. The ownership structure has profound financial implications. As a partner in an entity taxed as a partnership (like an LLC), you don’t receive a salary; you receive K-1 distributions. Your K-1 form reports your share of the business’s income, deductions, and credits, which flow through to your personal tax return.
When you combine this with the depreciation strategies above, the year-one tax picture can be dramatic. Imagine a new digital pathology lab capitalized with $2 million in equipment. That $2 million deduction passes through to the partners via their K-1s. If you are a 25% partner, you receive a $500,000 “paper loss” on your K-1, which can offset your clinical income and other investment gains.
This is how physician-owned ancillary services are built. The massive, front-loaded depreciation deductions shelter income during the critical first few years as the business ramps up.
The Trap: Passive Activity Loss (PAL) rules under §469. If you are just a silent investor and do not “materially participate” in the lab’s operations, your ability to deduct these losses against your active clinical income may be limited. Your CPA needs to analyze your specific involvement to determine if your participation level qualifies you to take the deductions in the current year.
Cost Segregation: Unlocking Hidden Depreciation in Your Lab Facility
If your digital pathology expansion involves buying or building out a new facility, you can supercharge your depreciation deductions with a cost segregation study. Normally, a commercial building is depreciated over a slow 39-year timeline. A cost segregation study is an engineering-based analysis that identifies components of the building that can be reclassified into shorter-lived asset classes.
For example, in a $3 million lab facility, the study might identify:
- 5-year property: Specialized electrical wiring for scanners, custom cabinetry, specific lab plumbing, carpeting.
- 7-year property: Office furniture and fixtures.
- 15-year property: Land improvements like parking lots and landscaping.
An experienced firm can often reclassify 20-30% of a building’s cost basis into these shorter categories. A $3M building might yield $750,000 in assets that can be moved from a 39-year schedule to a 5, 7, or 15-year schedule. Better yet, these reclassified assets are now eligible for 100% bonus depreciation. This means you could potentially deduct that entire $750,000 in year one, in addition to the normal (slow) depreciation on the remaining building structure.
The Trap: Using a cheap, non-engineering-based firm for the study. The IRS requires a detailed, defensible report. A low-quality study that misclassifies assets can be unwound in an audit, leading to back taxes, penalties, and interest. Use a reputable engineering firm that specializes in this work and will defend their report if challenged.
The 199A QBI Deduction: Understanding the Physician Phase-Out
We touched on this earlier, but it deserves its own section because it’s one of the most significant tax law changes for physicians in decades. The Section 199A Qualified Business Income deduction allows owners of pass-through businesses (S-corps, partnerships) to deduct up to 20% of their qualified business income.
For a non-physician business owner with $500,000 of pass-through income, this could mean a $100,000 deduction, saving them $37,000 in tax at the top bracket.
However, as mentioned, physicians are an SSTB. The 2026 phase-out for SSTBs begins at a taxable income of $246,850 (single) / $493,700 (joint) and is completely gone by $394,350 (single) / $787,700 (joint). The vast majority of practicing pathologists will have income above this threshold and will receive zero QBI deduction from their clinical practice income.
This is precisely why the alternative strategies discussed—like the equipment leasing entity—are so critical. By isolating a non-SSTB activity (equipment rental) from the SSTB activity (providing medical services), you may be able to reclaim this powerful deduction on at least a portion of your business enterprise’s income.
The Trap: Assuming you get the deduction. Many physicians hear “20% pass-through deduction” and incorrectly factor it into their financial planning. For nearly every practicing physician, the QBI from their clinical work is zero. You must plan your tax strategy around this reality and actively work with advisors to build structures that generate non-SSTB income where possible.
Adopting digital pathology AI is a landmark decision for any practice. It requires clinical validation, workflow redesign, and, most importantly, a sophisticated financial strategy. By pairing the right technology with the right tax and ownership structure, you can turn a major capital expense into a powerful engine for financial growth and clinical innovation.
Free GigHz Tools That Pair With This Article
Three free tools that complement the material above:
- ACR Appropriateness Criteria Lookup — Type an indication or clinical scenario in plain language and get the imaging studies the ACR rates for it, with adult and pediatric radiation levels. Built directly from 297 ACR topics, 1,336 clinical variants, and 15,823 procedure ratings.
- GigHz Imaging Protocol Library — A searchable library of 131 imaging protocols with the physics specs surfaced and the matching ACR Appropriateness Criteria alongside. Plain-English narratives readable in 60 seconds, organized by modality.
- GigHz Radiation Dose Calculator — Pick the imaging studies a patient has had and see total dose in millisieverts (mSv) with comparisons to natural background radiation, transatlantic flights, and chest X-rays. Useful for shared decision-making.
Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 21, 2026
